Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AB 101

Drug Profile

AB 101

Alternative Names: AB-101; AB-101 AD1; AB-101 EB1; AB-101a; AB-101b

Latest Information Update: 13 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alphyn Biologics
  • Class Anti-inflammatories; Antibacterials; Antipruritics; Skin disorder therapies
  • Mechanism of Action Cytokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis
  • Phase I Epidermolysis bullosa

Most Recent Events

  • 07 Mar 2024 Efficacy data from a phase IIa trial in Atopic dermatitis released by Alphyn Biologics
  • 26 Jul 2023 Alphyn Biologics plans a phase IIb trial for Atopic dermatitis with secondary bacterial infection in USA, Australia, Canada, Europe and Japan (Topical)
  • 26 Jul 2023 Alphyn Biologics plans a phase IIb trial for Atopic dermatitis in USA, Australia, Canada, Europe and Japan (Topical)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top